Authors: Lortholary, A Maillard, P Delva, R Boisdron-Celle, M Perard, D Vernillet, L Besenval, M Gamelin, E

Citation: A. Lortholary et al., Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study, EUR J CANC, 36(14), 2000, pp. 1773-1780

Authors: Felizot, L Lortholary, A Tuchais, C Delva, R Gamelin, E

Citation: L. Felizot et al., Unique bone metastasis in the foot disclosing carcinoma of the rectum, PRESSE MED, 28(34), 1999, pp. 1879-1879

Authors: Gamelin, E Boissdron-Celle, M Guerin-Meyer, V Delva, R Lortholary, A Genevieve, F Larra, F Ifrah, N Robert, J

Citation: E. Gamelin et al., Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage, J CL ONCOL, 17(4), 1999, pp. 1105-1110

Authors: Viens, P Palangie, T Janvier, M Fabbro, M Roche, H Delozier, T Labat, JP Linassier, C Audhuy, B Feuilhade, F Costa, B Delva, R Cure, H Rousseau, F Guillot, A Mousseau, M Ferrero, JM Bardou, VJ Jacquemier, J Pouillart, P

Citation: P. Viens et al., First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial), BR J CANC, 81(3), 1999, pp. 449-456

Authors: Gravis, G Viens, P Delva, R Baume, D Blaise, D Ternier, F Houvenaeghel, G Brandely, M Resbeut, M Maraninchi, D

Citation: G. Gravis et al., rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: Response and enhancement of further chemosensitivity, ANTICANC R, 18(5B), 1998, pp. 3699-3704